m25

M 25 is a Smoothened (Smo) receptor antagonist.

TT15 is an agonist of the GLP-1R.

M-25 is a Smoothened antagonist and inhibitor of the Hedgehog pathway.

Sonidegib metabolite M25 is a smoothened (SMO) antagonist.

Anti-Mouse/Human IL-7 Antibody (M25) is a mouse-derived IgG2b antibody inhibitor that targets mouse or human IL-7.

AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM).

TRIM25 ligand-1 is a covalent ligand that forms a covalent bond with Cys498 in the PRYSPRY domain of TRIM25, thereby enhancing the auto-ubiquitination activity of TRIM25. TRIM25 ligand-1 shows selectivity for TRIM25 both in vitro and in live cell environments.

NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor, with a Kd of 1.2 nM for cyclophilin A, and demonstrates anti-HCV activity with an EC50 of 40 nM. It is applicable in research related to HCV infection.

δ receptor antagonist

CYM2503 is a positive allosteric modulator (PAM) of the GAL2 receptor that potentiates galanin-induced IP1 production in vitro. It has no affinity for the orthosteric galanin binding site of the receptor (as measured by its inability to displace iodinated galanin, or to induce IP1 accumulation on its own).

Diphenhydramine (Syntedril), a first-generation antihistamine possessing antiemetic, antitussive, anticholinergic, and sedative properties, is mainly used in the treatment of allergies. Diphenhydramine is also used in the management of drug-induced parkinsonism and other extrapyramidal symptoms.

KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor, with IC50 values of 71 nM, 19 nM, 69 nM, and 69 nM for KDM5A, KDM5B, KDM5C, and KDM5D, respectively. Multiple myeloma MM1S cells treated with KDOAM-25 citrate show increased global H3K4 methylation at transcriptional start sites and impaired proliferation [1].

KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor

KDOAM-25, a potent and highly selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM for KDM5A, 19 nM for KDM5B, 69 nM for KDM5C, and 69 nM for KDM5D, enhances global H3K4 methylation at transcriptional start sites and reduces proliferation in multiple myeloma MM1S cells.

TM-25659 is a modulator of transcriptional co-activator with PDZ-binding motif (TAZ), with anti-osteoporotic and anti-obesity activities.

YM-254890 (YM) is a natural product and a Gαq/11 protein inhibitor (IC50 < 0.6 μM) with high selectivity and cell permeability. YM-254890 inhibits ADP-induced platelet aggregation by blocking the P2Y1 signaling pathway, and is widely used in research on thrombosis, pain, and uveal melanoma.

PD153035 hydrochloride (ZM 252868) is a effective and selective inhibitor of EGFR (Ki: 5.2 pM, IC50: 29 pM); few influence against FGFR, PGDFR, InsR, CSF-1, and Src.

PD153035 (NSC-669364) hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR, PGDFR, InsR, CSF-1 and Src.

UM-259 is a STING inhibitor with an EC50 of 1.50 μM in THP1-Dual cells expressing wild-type STING. It blocks STING oligomerization and inhibits diABZI-induced phosphorylation of TBK1 and IRF3, thereby suppressing the transcription of IFNβ and IL6, and reducing IFNβ secretion. UM-259 can be used to study STING-dependent inflammation and neurological disorders.

ZM 253270 is an nonpeptide neurokinin A antagonist.

LM 2510 is a bioactive chemical.

KDOAM-25 trihydrochloride is a potent and highly selective inhibitor of histone lysine demethylase 5 (KDM5), targeting KDM5A (IC50: 71 nM), KDM5B (IC50: 19 nM), KDM5C (IC50: 69 nM), and KDM5D (IC50: 69 nM). It enhances overall H3K4 methylation at the transcription start site and hinders the proliferation of multiple myeloma [MM1S cells].

PCC0208018 is a novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not directly affecting tumor cell viability in vitro.

DDPM-2571 is a highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. DDPM-2571 was quickly distributed into the brain and was highly effective in the prevention of chemically-induced seizures (pentylenetetrazole and pilocarpine models) and 6-Hz convulsions. It demonstrated significant anxiolytic-like and antidepressant-like properties. DDPM-2571 had antinociceptive properties, both in the hot plate test and in the second phase of the formalin test.